Cramer's 'Mad Money' Follow-Up: Nov. 5

Every night on "Mad Money," Jim Cramer offers market commentary and general investment advice, and he makes calls on specific stocks, both of his own choosing and in response to viewer requests. He relies on his many years of experience and strong track record, and he takes full responsibility for his calls.

"I never shirk from admitting my mistakes; instead, I dwell on them to learn from them. I change my mind, I take losses, I own up to them," Cramer has said.

Here we track some of his calls from the previous episode of "Mad Money" and find out, at least in the very short term, how the stocks are performing. Keep in mind that Cramer might not have been recommending that viewers take immediate action on a stock. And, of course, it's up to the individual investor to do his or her own homework.

That said, here's how some of the stocks that Cramer talked about on Wednesday's "Mad Money" show fared today.

---

WellPoint(WLP Quote): Cramer said that the Republican win in New Jersey on Tuesday was a slap in the face of Democrats and strengthened his buy argument for WellPoint.

On Thursday, WellPoint added 95 cents, or 1.9%, to close at $50.90.

Tessera Technology(TSRA Quote): Cramer spoke with President and CEO Hank Nothhaft, who addressed the company's fourth-quarter earnings miss, which he attributed to a disconnect on expectations. According to Northhaft, things are still on the right track at Tessera, and Cramer saw a strong future ahead for the company, though he scolded Nothhaft for promising too much and not delivering with its earnings.

On Thursday, Tessera closed up $1.44, or 6.9%, at $22.31.

ImmunoGen(IMGN Quote): Cramer spoke with President and CEO Dan Junius, who said the company likely would not be taken over. Cramer called the cancer drug company a speculative play, and Junius agreed, though he noted that in general, biotechs are speculative. Cramer said the stock is a speculative buy ahead of its December clinical data.